Annexon Inc
ANNXHealthcare|Biotechnology|USA
$5.79
-0.14 (-2.36%)
Tangible Book
$1.26
Earnings Power
$0.88
Clinical Trials (15)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06510816 A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) | Geographic Atrophy | P3 | Active | 659 | RCT, Double-blind | Vonaprument |
| NCT07020819 An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study) | Guillain-Barre Syndrome | P3 | Recruiting | 30 | Open-label | Tanruprubart |
| NCT04701164 Efficacy and Safety of ANX005 in Subjects With Guillain-Barré Syndrome | Guillain-Barre Syndrome | P3 | Completed | 242 | RCT, Double-blind | ANX005, Placebo |
| NCT04691570 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA) | Warm Autoimmune Hemolytic Anemia (wAIHA) | P2 | Completed | 7 | Open-label | ANX005 |
| NCT04656561 A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy | Geographic Atrophy | P2 | Completed | 270 | RCT, Double-blind | ANX007 |
| NCT04569435 Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | P2 | Completed | 17 | Open-label | ANX005 |
| NCT04514367 An Open Label Study of ANX005 in Subjects With, or at Risk for, Manifest Huntington's Disease | Huntington Disease | P2 | Completed | 28 | Open-label | ANX005 |
| NCT04035135 A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (GBS) | Guillain-Barré Syndrome | P1 | Completed | 14 | Open-label | ANX005, Intravenous immunoglobulin |
| NCT05521269 Dose Study of ANX1502 in Healthy Volunteers | Healthy | P1 | Completed | 135 | RCT, Double-blind | ANX1502, Placebo |
| NCT04535752 A Single and Multiple Ascending Dose Study of ANX009 in Normal Healthy Volunteers (NHV) | Safety and Tolerability in Healthy Volunteers | P1 | Completed | 48 | RCT, Double-blind | ANX009, Placebo |
| NCT03010046 Single Dose Study of ANX005 in Healthy Volunteers | Safety and Tolerability in Healthy Volunteers | P1 | Terminated | 27 | RCT, Double-blind | ANX005, IVIg, Placebos |
| NCT05288881 Single Ascending Dose Study of ANX105 | Healthy | P1 | Completed | 23 | RCT, Double-blind | ANX105, Placebo |
| NCT03488550 Single-dose Study of ANX007 in Participants With Primary Open-angle Glaucoma | Open-angle Glaucoma | P1 | Completed | 9 | Open-label | ANX007 |
| NCT04188015 Study of ANX007 in Participants With Primary Open-angle Glaucoma | Open Angle Glaucoma | P1 | Completed | 17 | RCT, Double-blind | 2.5mg ANX007, 5.0mg ANX007 |
| NCT05780515 A Study of ANX009 in Adult Participants With Lupus Nephritis | Lupus Nephritis | P1 | Completed | 7 | Open-label | ANX009 |